Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
IPO Year:
Exchange: NYSE
Website: abbott.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $130.00 | Outperform | Oppenheimer |
| 9/19/2024 | $131.00 | Overweight | Piper Sandler |
| 7/30/2024 | Buy → Hold | Edward Jones | |
| 5/30/2024 | $121.00 | Buy | Goldman |
| 7/21/2023 | Underperform → Peer Perform | Wolfe Research | |
| 5/30/2023 | $112.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/20/2023 | $125.00 → $127.00 | Overweight | Barclays |
| 4/20/2023 | $107.00 → $103.00 | Underperform | Wolfe Research |
| 4/20/2023 | $132.00 → $133.00 | Outperform | Bernstein |
| 4/20/2023 | $118.00 → $122.00 | Overweight | JP Morgan |
The test, run on Abbott's portable i-STAT® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concussion, producing lab-quality results in 15 minutesThe test will be used by healthcare professionals in the medical facilities at all MotoAmerica races in 2025ABBOTT PARK, Ill., and IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and MotoAmerica, the premier motorcycle road racing series in North America, announced today that MotoAmerica is the first professional sports organization worldwide to use Abbott's groundbreaking blood test to help assess suspe
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizationsIntegration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflowsABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE:ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collab
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemakerEnrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) leadConduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythmSAN DIEGO, April 27, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstra
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA SystemThe 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA SystemThe data were presented at the 2025 Heart Rhythm Society (HRS) annual meetingABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib). The data also highlights the excellent saf
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe
TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizationsThe latest results highlight significant improvements in tricuspid regurgitation and quality of life through two yearsABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years.
Abbott's Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillationPulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heartAbbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and targeted tissueABBOTT PARK, Ill., March 27, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). W
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this conditionAbbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockagesAbbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteriesABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotrip
Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
DEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)
DEF 14A - ABBOTT LABORATORIES (0000001800) (Filer)
144 - ABBOTT LABORATORIES (0000001800) (Subject)
10-K - ABBOTT LABORATORIES (0000001800) (Filer)
144 - ABBOTT LABORATORIES (0000001800) (Subject)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00
Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00
Edward Jones downgraded Abbott Labs from Buy to Hold
Goldman initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $121.00
Wolfe Research upgraded Abbott Labs from Underperform to Peer Perform
Morgan Stanley downgraded Abbott Labs from Overweight to Equal-Weight and set a new price target of $112.00
Barclays reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $127.00 from $125.00 previously
Wolfe Research reiterated coverage of Abbott Labs with a rating of Underperform and set a new price target of $103.00 from $107.00 previously
Bernstein reiterated coverage of Abbott Labs with a rating of Outperform and set a new price target of $133.00 from $132.00 previously
JP Morgan reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $122.00 from $118.00 previously
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross margin of 57.1 percent, which reflects a 140 basis point increaseReported operating margin of 16.3 percent of sales; adjusted operating margin of 21.0 percent, which reflects a 130 basis point increaseABBOTT PARK, Ill., April 16, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2025. First-quarter sales increased 4.0 percent on a reported basis, 6.9 pe
ABBOTT PARK, Ill., March 26, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2025 financial results on Wednesday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medi
Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of
ABBOTT PARK, Ill., Feb. 21, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 59 cents per share. This marks the 405th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2025, to shareholders of record at the close of business on April 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
Fourth-quarter sales of $11.0 billion; full-year 2024 sales of $42.0 billionFourth-quarter reported sales increased 7.2 percent; organic sales growth for the underlying base business increased 10.1 percent1Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent2Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%ABBOTT PARK, Ill., Jan. 22, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the fourth quarter ended Dec. 31, 2024. Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and 10.1 percent on an organic basis
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,
Dividend increased by 7.3%Quarterly dividend payout has increased more than 60% since 2020404th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend payout has increased more than 60% since 2020. This marks Abbott's 53rd consecutive year of dividend growth. It will be the 404th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 14, 2025, to shareholders of record at the close of business on Jan. 15
Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical dataABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the third quarter ended Sept. 30, 2024. Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding
ABBOTT PARK, Ill., Sept. 25, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2024 financial results on Wednesday, Oct. 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medic
ABBOTT PARK, Ill., Sept. 19, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 403rd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfoli
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime
Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives." "A
Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice P
LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le
ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board, effective today. Miles D. White, executive chairman and former CEO, will step down from the Abbott Board effective today and will retire after a remarkable 38-year career with the Company. "We're grateful for Miles' leadership and his exceptional work to transform Abbott into the leading health technology company that it is today," said William A. Osborn, lead director and chair of the Nominations and Governance committee. "Robert has continued to strengthen Abbott's position by advancing our industry-leading pip
PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “